相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Imaging Leucine-Rich Repeat Kinase 2 In Vivo with 18F-Labeled Positron Emission Tomography Ligand
Zhen Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2023)
Development and biological evaluation of[18F]FMN3PA & [18F] FMN3PU for leucine-rich repeat kinase 2 (LRRK2) in vivo PET imaging
Noeen Malik et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
18F-Labelled pyrrolopyrimidines reveal brain leucine-rich repeat kinase 2 expression implicated in Parkinson's disease
Xueyuan Chen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1
Jonas Walter et al.
CELL REPORTS (2021)
LRRK2 in Parkinson disease: challenges of clinical trials
Eduardo Tolosa et al.
NATURE REVIEWS NEUROLOGY (2020)
The In Situ Structure of Parkinson's Disease-Linked LRRK2
Reika Watanabe et al.
CELL (2020)
Lewis Acid-Facilitated Radiofluorination of MN3PU: A LRRK2 Radiotracer
Noeen Malik et al.
MOLECULES (2020)
Synthesis and Preliminary Evaluation of [11C]GNE-1023 as a Potent PET Probe for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2) in Parkinson's Disease
Zhen Chen et al.
CHEMMEDCHEM (2019)
Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease
Sofia Domingos et al.
FUTURE MEDICINAL CHEMISTRY (2019)
The genetic landscape of Parkinson's disease
A. Lunati et al.
REVUE NEUROLOGIQUE (2018)
Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling
Daniel C. Berwick et al.
MOLECULAR NEURODEGENERATION (2017)
A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci
Diana Chang et al.
NATURE GENETICS (2017)
Model selection criteria for dynamic brain PET studies
Sandeep S. V. Golla et al.
EJNMMI PHYSICS (2017)
Synthesis of [11C]HG-10-102-01 as a new potential PET agent for imaging of LRRK2 enzyme in Parkinson's disease
Min Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Kinetic Analysis and Quantification of [11C]Martinostat for in Vivo HDAC Imaging of the Brain
Hsiao-Ying Wey et al.
ACS CHEMICAL NEUROSCIENCE (2015)
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibitions
Matthew J. Fell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs
Changning Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The INIA19 template and NeuroMaps atlas for primate brain image parcellation and spatial normalization
Torsten Rohlfing et al.
FRONTIERS IN NEUROINFORMATICS (2012)
Kinases as Targets for Parkinson's Disease: From Genetics to Therapy
Renee Vancraenenbroeck et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2011)
Lrrk2 localization in the primate basal ganglia and thalamus: A light and electron microscopic analysis in monkeys
H. Lee et al.
EXPERIMENTAL NEUROLOGY (2010)
Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain
Shinji Higashi et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Distribution of PINK1 and LRRK2 in rat and mouse brain
Jean-Marc Taymans et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
Elisa Greggio et al.
NEUROBIOLOGY OF DISEASE (2006)
Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology
A Zimprich et al.
NEURON (2004)
分享论文
